Boehringer Ingelheim Names New U.S. President
Randolph Legg replaces Everett Hoekstra, who played a key role in the 2017 merger with Merial.
Randolph Legg has been promoted to president of U.S. operations at Boehringer Ingelheim Animal Health, the world’s second-largest animal health company.
Legg, a 26-year veteran of Boehringer Ingelheim’s human and veterinary pharmaceutical divisions, replaced Everett Hoekstra, CPA, who retired after two years in the job. Hoekstra helped integrate Merial Ltd. after the two companies merged in 2017.
Legg started with Boehringer Ingelheim in 1995 as a senior specialty sales account manager and climbed the corporate ladder to become head of the U.S. Animal Health Commercial Business in 2020, a position he continues to hold.
“It’s my honor to lead an organization dedicated to enhancing the well-being of people and animals,” Legg said.
Boehringer Ingelheim also announced the appointment of Helmut Finkler, Ph.D., as head of Regional Bio Manufacturing Americas and Global Manufacturing Science and Technology. He will oversee vaccine production sites in Athens, Georgia; Gainesville, Georgia; St. Joseph, Missouri; and Guadalajara, Mexico, the company stated.
Legg and Finkler will report to Jean-Michel Boers, president and CEO of Boehringer Ingelheim USA Corp.
Among the company’s animal health products are the Recombitek and Purevax lines of vaccines, parasiticides such as NexGard and Frontline, and the Aservo EquiHaler for asthmatic horses.
Did you know a subscription to Today’s Veterinary Business is free to qualified veterinary professionals? All you have to do is sign up here (and renew each year). You also can sign up to receive the Today’s Veterinary Business weekly e-newsletter.